CDK4/6 inhibition
Showing 1 - 25 of >10,000
COVID-19 Trial in Brandenburg an der Havel (Palbociclib)
Withdrawn
- COVID-19
-
Brandenburg an der Havel, GermanyUniversitätsklinikum Brandenburg an der Havel
Nov 3, 2022
Inhibition of Autophagy Synergizes Anti-tumor Effect Trial in Guangzhou (100mg bid dose of hydroxychloroquine combined with
Recruiting
- Inhibition of Autophagy Synergizes Anti-tumor Effect
- 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
- RP2D dose of 100mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jul 19, 2023
Associated With First-Line CDK4/6 Inhibition and Hormonal
Not yet recruiting
- Metastatic Breast Cancer
- Palbociclib + aromatase inhibitor
- Aromatase inhibitor
-
New York, New YorkPfizer
Sep 7, 2021
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in Duarte
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +3 more
- Abemaciclib
- Questionnaire Administration
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 1, 2022
Breast Cancer Trial in Amsterdam, Groningen (FES-PET scan, and possibly one additional visit for an FDG-PET)
Recruiting
- Breast Cancer
- FES-PET scan, and possibly one additional visit for an FDG-PET
-
Amsterdam, Netherlands
- +1 more
Jan 11, 2022
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 Trial in San
Recruiting
- Castration-Resistant Prostate Carcinoma
- +6 more
- Abemaciclib
- Lutetium Lu 177-PSMA-617
-
San Francisco, CaliforniaUniversity of California, San Francisco
Sep 8, 2022
Metastatic Breast Cancer, Breast Carcinoma Trial in United States (LEE-011, Fulvestrant, Placebo)
Active, not recruiting
- Metastatic Breast Cancer
- Breast Carcinoma
- LEE-011
- +2 more
-
Birmingham, Alabama
- +12 more
Feb 17, 2022
Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer Trial in United Kingdom (Ipatasertib 300mg, Fulvestrant
Not yet recruiting
- Metastatic Breast Cancer
- +2 more
- Ipatasertib 300mg
- +3 more
-
Cambridge, Cambridgeshire, United Kingdom
- +19 more
Jun 3, 2021
Breast Tumor Female Trial in Netherlands (CDK 4/6 inhibitor, Non-Steroidal Aromatase Inhibitor, Fulvestrant)
Active, not recruiting
- Breast Neoplasm Female
- CDK 4/6 inhibitor
- +2 more
-
Alkmaar, Netherlands
- +71 more
Apr 1, 2022
CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent
Not yet recruiting
- Breast Cancer
- +3 more
- Different treatment regimens following progression on CDK4/6 inhibitors.
- (no location specified)
Sep 5, 2023
CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast
Not yet recruiting
- Breast Cancer
- CDK4/6 inhibitor
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;
Recruiting
- Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
- dalpiciclib; fluvestrant; compound gossypol acetate tablets
-
Hangzhou, Zhejiang, ChinazhejiangCH
Nov 9, 2023
Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)
Recruiting
- Locally Advanced Breast Cancer
- Hormone Receptor Positive，HER2-negative Breast Cancer
-
Jinan, Shandong, ChinaBreast Cancer Center, Shandong Cancer Hospital and Institute
Apr 11, 2023
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago
Not yet recruiting
- Estrogen-receptor-positive Breast Cancer
- +3 more
- elacestrant, palbociclib, abemaciclib, ribociclib
-
Chicago, IllinoisNorthwestern University
Sep 25, 2023
Learn About Use and Effects of CDK4/6 Inhibitors in Canadian
Active, not recruiting
- Breast Cancer
-
Kirkland, Quebec, CanadaPfizer Canada
Mar 5, 2023
Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)
Not yet recruiting
- Advanced HR+ HER2 Negative Breast Carcinoma
- (CDK)4/6 inhibitor
- (no location specified)
Sep 27, 2022
Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy
Recruiting
- Advanced Breast Cancer
- The combination of Dalpiciclib with physician-selected endocrine therapy
- Chemotherapy selected by the physician
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 22, 2023
Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)
Not yet recruiting
- Hormone Receptor-positive Advanced Breast Cancer
- chidamide combined with fulvestrant
- (no location specified)
Mar 28, 2023
Advanced Breast Cancer Trial in Lebanon (Fulvestrant, Neratinib, Alpelisib)
Not yet recruiting
- Advanced Breast Cancer
- Fulvestrant
- +4 more
-
Lebanon, New HampshireDartmouth Hitchcock Medical Center
Jun 28, 2023
Tumors Trial in Seoul (abemaciclib+paclitaxel)
Active, not recruiting
- Tumors
-
Seoul, Korea, Republic ofSeverance Hospital
May 30, 2022
Breast Cancer Trial in Baltimore (Endocrine Therapy and a CDK 4/6 inhibitor)
Recruiting
- Breast Cancer
- Endocrine Therapy and a CDK 4/6 inhibitor
-
Baltimore, MarylandJohns Hopkins University
Jul 18, 2022
Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality
Recruiting
- Breast Cancer Stage IV
- comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
-
Mansoura, Dakahlia, EgyptOncology center mansoura university
Jan 1, 2023
